Accustem Sciences Inc. (ACUT)
OTCMKTS: ACUT · Delayed Price · USD
0.410
+0.010 (2.50%)
Jul 2, 2024, 3:23 PM EDT - Market closed
Company Description
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing products for the treatment and management of various cancers.
Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients.
The company was founded in 2013 and is headquartered in New York, New York.
Accustem Sciences Inc.
Country | NY |
Founded | 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 3 |
CEO | Ms. Wendy E. Blosser |
Contact Details
Address: 5 Penn Plaza, 19th Floor, #1954 New York, New York 10001 United States | |
Phone | 442070661000 |
Website | accustem.com |
Stock Details
Ticker Symbol | ACUT |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001850767 |
CUSIP Number | 00444A101 |
ISIN Number | US00444A1016 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Wendy E. Blosser | Chief Executive Officer and Director |
Gabriele Marco Antonio Cerrone M.B.A. | Executive Chairman of the Board |
Joe Flanagan | Chief Business Officer |
Keeren Shah | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 20, 2024 | 10-Q | Quarterly Report |
May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Apr 10, 2024 | 8-K | Current Report |
Mar 22, 2024 | 10-K | Annual Report |
Nov 13, 2023 | 10-Q | Quarterly Report |
Aug 14, 2023 | 10-Q | Quarterly Report |
Jun 9, 2023 | 8-K | Current Report |
Jun 7, 2023 | 8-K | Current Report |
May 5, 2023 | 10-Q | Quarterly Report |
Apr 28, 2023 | 10-K/A | [Amend] Annual report |